Zongertinib (BI 1810631, BI-1810631) is a potent, selective HER2 inhibitor, binds to the TKD of HER2 while sparing wild-type EGFR.
Zongertinib (BI 1810631) is a potent and selective inhibitor of HER2-driven oncogenic signaling, efficiently blocks HER2 mutant-driven lung cancer.
reduces cell growth and survival in mutant HER2 driven Ba/F3 cell systems, in human tumor cell lines in vitro and translated into tumor regressions in a genome-engineered HER2-YVMA mutant xenograft model.
1. Wilding Birgit, et al. Synthesis of diazino-pyrimidines as anticancer agents: World Intellectual Property Organization, WO2021213800.
2. John Heymach, et al. Clin Lung Cancer. 2023 Mar;24(2):e65-e68.
